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Objective: To investigate the possibility that uric acid (UA) can impair endothelial function, an important
surrogate for atherosclerosis.
Design: UA was administered locally or systemically to healthy adult men and women in a series of
randomised placebo controlled studies. This temporarily raised serum UA concentrations, so that the
potential effects of hyperuricaemia on mechanisms of cardiovascular disease could be studied.
Main outcome measures: The effects of UA administration on basal blood flow and responses to locally
administered acetylcholine, sodium nitroprusside, and L-NG-monomethylarginine were studied in the
forearm vascular bed with venous occlusion plethysmography. The effects of hyperuricaemia on systemic
vascular resistance, large artery compliance, and baroreflex sensitivity were examined by validated non-
invasive techniques.
Results: UA administration caused a twofold increase in serum concentrations. However, there were no
acute effects on haemodynamic variables, basal forearm blood flow, or nitric oxide dependent endothelial
function.
Conclusion: Unlike other risk factors associated with endothelial dysfunction, acute exposure to high
concentrations of UA does not impair cardiovascular function in healthy men. These findings do not
support a causal link between hyperuricaemia and atherosclerosis.
U
ric acid (UA) is formed as a natural product of purine
metabolism. Humans are exposed to comparatively
high serum and tissue concentrations because of the
lack of urate oxidase, an enzyme that is responsible for
further metabolism of UA in virtually all other species.1 A
physiological role of UA has been suggested on the basis of its
potent antioxidant properties,2 although this potential benefit
may be gained at the cost of an increased risk of joint and
kidney disease. Epidemiological studies have identified a
strong relation between hyperuricaemia and subsequent
cardiovascular disease risk in unselected populations3–5 and
high risk groups, including patients with hypertension,
diabetes mellitus, and chronic cardiac failure.6–8 This relation
has been attributed to associations between UA and potential
confounding risk factors.3 However, several epidemiological
studies have shown that the predictive power of hyper-
uricaemia persists, even after considering these risk factors.4 5
The distinction between UA as a coincidental or causal risk
factor is important because, if UA is causal, treatment to
lower serum UA concentrations may potentially reduce
cardiovascular disease risk. Epidemiological studies are
unlikely to resolve this issue. Given the high prevalence of
cardiovascular disease, there is a pressing need to identify
additional treatable risk factors. The role of UA in the
cardiovascular system is poorly understood and potential
mechanisms by which it may promote atherogenesis have
received little attention.9
In health, the endothelium plays a pivotal part in
regulating the cardiovascular system through the release of
nitric oxide, which causes vasodilatation, inhibits platelet
aggregation, and reduces local vascular inflammation.10
Impaired blood flow responses to endothelium dependent
vasodilators are a characteristic finding in patients with any
one of several major cardiovascular risk factors and are
thought to be an important early step in the development of
atherosclerosis.11 12 Disruption of endothelium dependent
nitric oxide bioavailability also manifests as reduced large
artery compliance13 and impaired baroreflex sensitivity
(BRS).14 An inverse relation between serum UA concentra-
tion and nitric oxide activity has been identified,15 and it is
therefore possible that UA directly influences endothelial
function, either by causing endothelial dysfunction or, as an
antioxidant, by protecting against the impairment of
endothelial function. One study has reported a lower
cardiovascular mortality among patients with heart failure
treated with allopurinol and the authors attributed this to
lowering of serum UA,16 although there may be other
explanations. The feasibility of administering UA in solution,
for clinical studies, has recently been established.17 The
purpose of the present research was to determine whether
raised UA concentrations disrupt nitric oxide mediated
vascular function, in the same manner as established
cardiovascular risk factors. Therefore, the cardiovascular
effects of acute hyperuricaemia were studied in healthy




The local research ethics committee granted approval for the
studies and written informed consent was obtained from
each participant. The investigation conforms to the principles
outlined in the Declaration of Helsinki. Participants were
recruited from a community database of healthy volunteers
held at the Clinical Research Centre of the University of
Edinburgh. Studies were performed in the morning, after an
overnight fast, in a quiet room maintained at 24–26 C˚.
Inclusion criteria were male or female sex and age 18 to 45
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: ACh, acetylcholine; BP, blood pressure; BRS, baroreflex
sensitivity; L-NMMA, L-NG-monomethylarginine; PI, pulse interval; SNP,
sodium nitroprusside; UA, uric acid
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years. Exclusion criteria were increased blood pressure (BP)
(. 160/100 mm Hg), clinical history of joint, kidney or
cardiovascular disease, any medication being taken, regular
tobacco use, serum creatinine . 110 mmol/l, or serum UA
. 400 mmol/l.
Intra-arterial drug administration
The brachial artery of the non-dominant arm was cannulated
with a 27 standard wire gauge steel needle (Cooper’s Needle
Works Ltd, Birmingham, UK) under local anaesthesia by an
aseptic technique. Vasoactive drugs were administered
through a 16 gauge epidural catheter (Portex Ltd, Kent,
UK) connected to an IVAC P1000 syringe pump (Alaris
Medical Ltd, Hampshire, UK).11 Saline was infused for 30
minutes at the start of the study and for 20 minutes between
drugs to establish baseline blood flow. Vasoactive drugs were
infused for six minutes at each dose and the rate of infusion
was kept constant at 1 ml/min throughout.
Measurement of forearm blood flow
Blood flow was measured in both forearms by venous
occlusion plethysmography, as previously described.11 18
Measurements were taken during the last three minutes of
each six minute infusion. The last five recordings were
averaged to determine flow in each arm. Responses were
expressed as percentage change from baseline, where the
ratio of blood flow in the infused to that in the non-infused
limbs was considered, to account for any systemic effects.11
Systemic vascular resistance
BP was recorded in the dominant arm with a validated
oscillometric device (HEM-705CP, Omron, Kyoto, Japan).19
Cardiac index was assessed by transthoracic bioimpedance
(NCCOM3-R7, BoMed, Irvine, California, USA).20 The sys-
temic vascular resistance index was calculated as the mean
arterial pressure divided by the cardiac index.
Pulse wave analysis
The dominant radial artery pulse waveform was assessed by
applanation tonometry (SPC-301 micromanometer, Millar
Instruments, Houston, Texas, USA). A corresponding aortic
pressure waveform was generated by pulse wave analysis
software (SphygmoCor, PWV, Sydney, Australia).21 The
augmentation index is a validated measure of large artery
stiffness, calculated as the difference between the first and
second central systolic BP peaks, expressed as a percentage of
pulse pressure.22
Spontaneous BRS
Study participants rested supine. Systolic BP was recorded
continuously by a Portapres system (TNO, Amsterdam, the
Netherlands) and an ECG was measured simultaneously.23 24
Signals from both devices were recorded over 15 minutes and
analysed off line by Chart HRV software (ADInstruments,
Hastings, UK). BRS was determined by two independent
methods. Parallel increases or decreases in BP and pulse
interval (PI) are thought to represent spontaneous baroreflex
activity.25 Sequences of parallel increases or decreases over
two or more consecutive beats were analysed and the
resulting slope (nPI/nBP) was used to represent BRS by
sequence analysis.25 Fast Fourier transformation of BP and PI
data gave the total spectral power of the variability of each
and the formula (powerBP/powerPI)
K gave spontaneous BRS
by spectral analysis.26
Measurement of biochemical variables
Blood was collected in gel tubes (Sarstedt Ltd, Leicester, UK),
allowed to clot, and centrifuged at 1000 g for 10 minutes.
Serum was separated and UA concentration was determined
by a colorimetric dry slide method (Vitros, Ortho-Clinical
Diagnostics, Amersham, UK).
Drugs and reagents
UA and lithium carbonate (Ultrapure preparations, Sigma
Chemical Company, Poole, UK) were reconstituted in a sterile
dextrose solution (Baxter Healthcare, Norfolk, UK) and
filtered (0.22 mm Millex, Millipore, Molsheim, France).
The drugs used were acetylcholine (ACh; CIBAVision-
Ophthalmics, Southampton, UK), sodium nitroprusside
(SNP; David Bull Laboratories, Warwick, UK), and L-NG-
monomethylarginine (L-NMMA; Calbiochem-Novobiochem,
Nottingham, UK).
Basal forearm blood flow
Six healthy men aged 29 (4) years (SEM) were recruited to a
two way randomised placebo controlled study. Participants
underwent intra-arterial administration of saline for 20
minutes to establish baseline blood flow, followed by
infusion of 0, 0.5, 1.0, 2.0, and 4.0 mg/min UA in 4%
dextrose/0.1% lithium carbonate vehicle for six minutes at
each dose and for 12 minutes at the maximum dose. Forearm
blood flow was assessed at baseline and during each infusion.
Local hyperuricaemia and endothelial function
Ten healthy men were recruited to a two way randomised
placebo controlled study. They underwent intra-arterial
administration of saline for 30 minutes to establish baseline
blood flow, followed by ACh 7.5, 15, and 30 mmol/min, SNP
2, 4, and 8 mmol/min, and L-NMMA 2 and 4 mmol/min,
where the order of infusion of ACh and SNP was randomised
between subjects. Drug infusions were separated by saline for
20 minutes to allow restoration of basal blood flow. Drugs
were infused for six minutes at each dose.11 UA 2.0 mg/min
in 4% dextrose/0.1% lithium carbonate vehicle or vehicle
alone was co-infused locally. Effluent venous blood (5 ml)
was collected from each forearm during infusion for UA
measurement.
Systemic hyperuricaemia and endothelial function
Ten healthy men were recruited to a two way randomised
placebo controlled study. An 18 standard gauge venous
cannula was inserted into a suitable vein in each antecubital
fossa under local anaesthetic. Participants underwent sys-
temic administration of 1000 mg UA in 4% dextrose/0.1%
lithium carbonate vehicle or vehicle alone over one hour
through the cannula in the non-dominant forearm.
Immediately after infusion, endothelial function was studied
as described above. Venous blood (5 ml) was drawn from the
non-infused forearm cannula at baseline, immediately after
infusion, and one hour after infusion for UA measurement.
Systemic haemodynamic variables
Eight healthy men were recruited to a three way randomised
placebo controlled study. An 18 standard gauge venous
cannula was inserted into a suitable vein in each antecubital
fossa under local anaesthetic. Portapres finger cuff and
BoMed electrodes were applied. Participants rested supine for
30 minutes, then underwent systemic administration of
1000 mg UA in 500 ml 4% dextrose/0.1% lithium carbonate
vehicle, vehicle alone, or 0.9% saline over one hour through
the non-dominant forearm cannula. Electrocardiogram and
Portapres signals were recorded for BRS determination at
baseline and at the end of the infusion. BP, cardiac index,
and pulse wave analysis (PWA) were measured at baseline
and at 15 minute intervals. Venous blood (5 ml) was drawn
through the non-infused forearm cannula at baseline and
immediately after infusion for UA measurement.
156 Waring, Adwani, Breukels, et al
www.heartjnl.com
Data analysis and statistics
Numbers of study participants were determined to give at
least 80% power to detect a 10% difference in the primary
outcome variables (forearm blood flow response to ACh,
augmentation index, and BRS). Responses were compared by
two way analysis of variance and paired Student’s t tests,
where appropriate. Significance was accepted at the 5% level
in all cases. All values are reported as mean (SEM).
RESULTS
Table 1 shows baseline characteristics of the study partici-
pants.
Basal blood flow
Local administration of neither vehicle nor UA had any effect
on basal forearm blood flow (fig 1). Local UA and vehicle
administrations caused systemic UA concentrations to rise by
62 (13) and 24 (3) mmol/l, respectively (p , 0.001); 69 mg
(about 410 mmol) UA was administered to each subject and
the mean volume of distribution was calculated to be 22.6
(2.0) l.
Local hyperuricaemia and endothelial function
Venous effluent UA concentrations in the infused and non-
infused forearms were 384 (7) and 280 (1) mmol/l, respec-
tively, during UA administration (p , 0.001) and 290 (4)
and 283 (1) mmol/l, respectively, during vehicle administra-
tion. This was an increase of 33 (3)% and of 21 (0)% during
UA and vehicle administration, respectively (p , 0.001).
Despite this, responses to ACh, SNP, and L-NMMA were
unaltered in the forearm vascular bed (fig 2).
Systemic hyperuricaemia and endothelial function
Serum UA concentrations before, immediately after, and one
hour after infusion were 227 (8), 534 (18), and 452
(11) mmol/l, respectively, for UA administration and 224
(27), 220 (27), and 217 (27) mmol/l, respectively, for vehicle
administration. These were increases of 145 (19)% and 24
(1)% for UA and vehicle, respectively (p , 0.001). Forearm
blood flow responses to ACh, SNP, and L-NMMA infusion
were not altered by systemic hyperuricaemia (fig 3).
Systemic haemodynamic variables
Baseline versus post-infusion serum UA concentrations were
336 (12) v 350 (1) mmol/l, 370 (17) v 361 (17) mmol/l, and 370
(16) v 627 (23) mmol/l (p , 0.001) for saline, vehicle, and UA
administration, representing increases from baseline of
24 (1)%, 22 (1)%, and 79 (7)%, respectively (p , 0.001).
Augmentation index, central systolic BP, BRS by sequence
analysis, and BRS by spectral analysis were not altered by
systemic hyperuricaemia (table 2). The systemic vascular
resistance index increased during all infusions, with a non-
significant trend towards lower increases during UA infusion
(table 2).
DISCUSSION
The importance of high serum UA concentration as a marker
of increased cardiovascular risk has been recognised for more
than 50 years.27 However, no biologically plausible causal link
to atherosclerosis has been shown in vivo. In the current
study, UA administration had no effect on basal forearm
blood flow or response to L-NMMA, indicating that short
lived hyperuricaemia does not have a direct impact on resting
vascular tone or basal nitric oxide release. Lack of effect on
endothelium dependent and endothelium independent vaso-
dilator responses suggests that high UA concentrations do
not affect vascular smooth muscle nitrate responsiveness or
stimulate nitric oxide release in health.
There is a strong association between disease states
characterised by loss of vascular nitric oxide activity and
high serum UA concentrations. The present findings indicate
that acute hyperuricaemia does not directly influence
constitutive, or stimulated, nitric oxide liberation from the
vascular endothelium. A previous study has shown that
enhancing vascular nitric oxide bioavailability by L-arginine
supplementation causes a reduction in circulating UA
concentrations.15 Therefore, UA may be responsive to vascular
nitric oxide activity, consistent with a non-causal association
between endothelial dysfunction and increased serum UA
concentrations. Furthermore, UA is an important intracel-
lular free radical scavenger during metabolic stress,28 for
example, in vascular smooth muscle and endothelial cells,29
and circulating concentrations are thought to be responsive
to the local redox state.30 31 Therefore, it is possible that
increased UA concentrations are a compensatory response, in
view of the antioxidant properties of UA.
Hyperuricaemia coexists with impaired large artery com-
pliance in several disease states characterised by reduced
vascular nitric oxide bioavailability. UA had no impact on the
large conduit vessels that determine pulse waveform con-
duction, suggesting that high concentrations are not causally
linked to increased vascular stiffness. BRS, determined by
two discrete methods,25 26 was unaffected by UA, consistent
with the lack of effect on constitutive nitric oxide activity and
large artery compliance, which are important vessel wall
properties that can influence BRS. The lack of effect on BRS
also indicates that baroreceptor function, and indeed cardiac
sensitivity to autonomic outflow, was not affected by local
Figure 1 Pilot study. Forearm blood flow, as the ratio of the infused to
the non-infused forearm, expressed as percentage change from baseline
during local administration of uric acid (UA; 0, 0.5, 1.0, 2.0, and
4.0 mg/min) in the vehicle (n = 6).













Number/men 10/10 10/6 8/8
Age (years) 23 (1) 24 (1) 30 (4)
Systolic BP (mm Hg) 110 (4) 107 (6) 108 (3)
Diastolic BP (mm Hg) 68 (5) 71 (4) 72 (3)
Heart rate (beats/min) 59 (2) 58 (3) 60 (2)
Body mass index (kg/m2) 23 (1) 22 (1) 23 (0)
Creatinine (mmol/l) 84 (4) 84 (6) 86 (3)
Glucose (mmol/l) 4.6 (0.2) 4.8 (0.1) 4.7 (0.3)
Cholesterol (mmol/l) 4.1 (0.2) 4.1 (0.2) 4.8 (0.2)
Uric acid (mmol/l) 258 (13) 252 (14) 366 (12)
Data are mean (SEM).
BP, blood pressure; UA, uric acid.
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increases in UA concentration, irrespective of vessel wall
conditions.
There are several important limitations of these findings.
This series of acute, mechanistic studies did not address the
effects of chronic exposure to increased serum UA concen-
trations, which may be a more important determinant of
future cardiovascular risk. However, it is less feasible to
examine chronic hyperuricaemia in a controlled manner
because of the potential risks of joint and kidney disease. A
further potential limitation is that the current studies
addressed the effects of an acute increase of UA in a young,
healthy population, free from major cardiovascular risk
factors. Nonetheless, if UA were an independent causal risk
factor for atherosclerosis, then its presence should be
expected to impair endothelial function. Other atherosclerotic
risk factors cause acute impairment of endothelial function in
young, healthy people—for example, increased homocysteine
concentrations after methionine administration32 or ingestion
Figure 2 Forearm blood flow responses to acetylcholine (ACh) 7.5, 15,
and 30 mg/min, nitroprusside (SNP) 2, 4, and 8 mg/min, and L-NG-
monomethylarginine (L-NMMA) 2 and 4 mmol/min, as a ratio of the
infused to the non-infused forearm and expressed as percentage change
from baseline during local co-administration of 2 mg/min UA in vehicle
or of vehicle alone (p = 0.74, 0.47, and 0.87, respectively; n = 10).
Figure 3 Forearm blood flow responses to ACh 7.5, 15, and 30 mg/
min, SNP 2, 4, and 8 mg/min, and L-NMMA 2 and 4 mmol/min, as a
ratio of the infused to the non-infused forearm and expressed as
percentage change from baseline after systemic administration of
1000 mg UA in vehicle or of vehicle alone (p = 0.87, 0.65, and 0.38,
respectively; n = 10).
Table 2 Systemic haemodynamic variables before and after systemic administration of 1000 mg UA in vehicle, vehicle alone,
or saline (n = 8)
Saline Vehicle UA
Baseline Postinfusion Baseline Postinfusion Baseline Postinfusion
SBP (mm Hg) 96 (3) 97 (3) 93 (2) 97 (5) 96 (4) 100 (4)
DBP (mm Hg) 61 (2) 65 (2) 63 (3) 68 (3) 62 (4) 71 (3)
HR (beats/min) 55 (3) 53 (3) 57 (4) 58 (3) 58 (3) 59 (2)
AIx (%) 26.7 (6.0) 23.1 (6.1) 22.6 (6.0) 21.1 (6.1) 23.6 (5.1) 26.1 (6.2)
CI (l/min/m2) 3.3 (0.2) 3.0 (0.2) 3.3 (0.4) 3.3 (0.3) 3.1 (0.2) 3.2 (0.3)
SVRI (au) 12.0 (1.0) 13.7 (0.9) 10.2 (1.5) 11.7 (2.0) 12.3 (1.0) 13.0 (1.0)
BRSseq (ms/mm Hg) 22.3 (4.7) 21.2 (4.0) 19.7 (4.9) 22.8 (5.0) 21.8 (4.4) 20.3 (4.4)
BRSspec (ms/mm Hg) 24.3 (5.8) 19.4 (3.4) 22.2 (6.6) 26.8 (6.4) 23.4 (5.0) 21.7 (5.9)
Data are mean (SEM).
AIx, augmentation index; au, arbitrary units; BRSseq, baroreflex sensitivity by sequence analysis; BRSspec, baroreflex sensitivity by spectral analysis; CI, cardiac
index; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SVRI, systemic vascular resistance index
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of a fatty meal.33 Additionally, amelioration of established
risk factors allows rapid restoration of endothelial function,
including correction of hypertension, hypercholesterolaemia,
or hyperhomocysteinaemia.
A further limitation is that the effects of raising UA
concentrations on endothelial function were studied only in
healthy men. Previous studies have shown that the relation
between hyperuricaemia and increased cardiovascular risk is
more apparent in women, in both unselected populations34
and those with established coronary artery disease.35
Additional research is required to investigate the effects of
raised serum UA concentrations on endothelial function in
women. Furthermore, the effects of raised serum UA
concentrations merit further investigation in men and
women with established cardiovascular risk factors.
The effects of raising UA concentrations may be modest
because of the comparatively high background concentra-
tions to which humans, as a species, are ordinarily exposed.
Further work is required to establish the cardiovascular
effects of lowering serum UA concentrations. Xanthine
oxidase inhibitors—for example, allopurinol—cause a mod-
est reduction in circulating UA concentrations. Xanthine
oxidase activity produces hydrogen peroxide, an important
source of free radicals in vivo,36 which confounds the relation
between xanthine oxidase inhibitors and UA lowering.
Methods that lower UA directly should allow more useful
interpretation of any cardiovascular effects—for example,
using urate oxidase, which causes rapid and substantial
reductions in circulating UA concentrations.37
In summary, high serum UA concentrations, at least in the
acute setting, do not impair cardiovascular function in
healthy men. These findings do not support a causal role
for UA in the development of atherosclerosis.
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